ReviewCureus2025
Efficacy of Tranexamic Acid in Reducing Blood Loss During Burn Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burn injuries remain a major global health challenge, with surgical interventions often requiring blood transfusions due to substantial intraoperative bleeding. Tranexamic acid (TXA), an antifibrinolytic agent, has demonstrated efficacy in reducing perioperative blood loss across various surgical specialties, but evidence in burn surgery remains limited and inconsistent. This systematic review and meta-analysis aimed to evaluate the hemostatic efficacy of TXA in burn patients undergoing surgical procedures. A comprehensive literature search was conducted across PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) databases from the inception of databases to June 2025. Randomized controlled trials comparing TXA to placebo or no intervention in burn patients undergoing surgical procedures were included. Data extraction focused on intraoperative blood loss, hemoglobin changes, and hematocrit changes. Quality assessment was performed using the Cochrane Risk of Bias 2.0 tool, and meta-analyses were conducted using random-effects models. Four randomized controlled trials encompassing 264 participants were included, with 130 patients receiving TXA and 134 controls. The pooled analysis demonstrated that TXA significantly reduced intraoperative blood loss with a mean difference of -181.60 mL (95% CI: -267.34 to -95.86; p < 0.0001). TXA was also associated with significantly smaller declines in hemoglobin levels compared to controls (mean difference: -1.02 g/dL; 95% CI: -1.39 to -0.65; p < 0.00001). These findings suggest that TXA provides meaningful hemostatic benefits in burn surgery, although larger multicenter trials are needed to validate these results and assess long-term safety outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.